Searched for
CARTIKEYA REDDY
- Buy Dr. Reddy's Laboratories, target Rs 2715.0 : Siddharth BhamreBuy Dr. Reddy's Laboratories Ltd. at a price target of Rs 2715.0 and a stop loss at Rs 2560.0 from entry point
- Sell Dr. Reddy's Laboratories, target Rs 2577.0 : Deen Dayal InvestmentSell Dr. Reddy's Laboratories Ltd. at a price target of Rs 2577.0 and a stop loss at Rs 2650 from entry point
Make in India: Can India be a hub for the $200 billion worth biosimilars opportunityThe Indian biogenerics industry is poised to exploit the opportunity they did in the case of generics, although it has no clear advantage a...
- How Dr Reddy’s is rebooting its biosimilars playDr Reddy’s was among the first to race off the blocks with four launches in India about as many years. But things have slowed since.
- Pharma majors tying up with colleges to cut R&D expensesPharma companies are increasingly forging alliances with universities and science institutions to cut their mounting research and developme...
- The perfect time to make it bigIndia is the flavour of the season for the international business world. After the IT boom, now it’s the turn of the biotech sector. The la...
- DRL to launch biosimilar drugs in Europe by '10India's largest drug maker, Dr Reddy’s Laboratories, is planning to introduce its first biosimilar drug by 2010 in Europe, a senior company...
- Now, make way for the biotech copycatsIndian drug makers have already become a formidable force in bringing out generic forms of chemically-synthesised medicines, especially in ...
- DRL plans high-margin drugs for India, EuropeDr Reddy’s Laboratories (DRL) is focussing on high-margin speciality drugs and plans to launch biosimilar drugs in India and Europe.
- Dr Reddy's developing 8 more biotech drugsDr. Reddy's Laboratories developing eight generic medicines using biotechnology.
Load More
